Rochem International Inc DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News

Rochem Partner Marks Key Achievement

18 Oct 2024

// PRESS RELEASE

CPHI WW 2024 ~ Milan, Italy

18 Oct 2024

// PRESS RELEASE

Rochem Makes the cover of Long Island Press Business!

08 Aug 2024

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

CPhI WW Frankfurt

Booth #12.0F117

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

1 Interview #SpeakPharma, 7 Corporate Content #SupplierSpotlight, 1 Data Compilation #PharmaFlow, 20 News #PharmaBuzz

media
1 Interview #SpeakPharma
7 Corporate Content #SupplierSpotlight
1 Data Compilation #PharmaFlow
20 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

212 All APIs, 1 CEP/COS, 211 Listed APIs

212 All APIs
1 CEP/COS
211 Listed APIs

KEY PRODUCTS

Afoxolaner, Calcium Folinate, Clorsulon, Dalbavancin, Docetaxel, Firocoxib, Fluralaner, Liraglutide, Methotrexate, Oclacitinib Maleate, Pemetrexed, Pemetrexed Dipotassium, Pemetrexed Disodium, Pemetrexed Ditromethamine, Semaglutide, Tirzepatide

Afoxolaner
Calcium Folinate
Clorsulon
Dalbavancin
Docetaxel
Firocoxib
Fluralaner
Liraglutide
Methotrexate
Oclacitinib Maleate
Pemetrexed
Pemetrexed Dipotassium
Pemetrexed Disodium
Pemetrexed Ditromethamine
Semaglutide
Tirzepatide

SERVICES

Sales, Marketing, Registration

pharmaServices
Sales, Marketing, Registration

EXCIPIENTS

27 Listed Products

excipientPortfolio
27 Listed Products

EXCIPIENTS BY INGREDIENTS

Gum Arabic, Carrageenan, Mannitol, Aspartame Excipient, Erythritol Excipient, Carboxymethyl cellulose excipient, Locust Bean Gum, Sucralose, Trehalose, Stevia Excipient, Lactitol Excipient, Guar Gum Excipient, Acesulfame Potassium, Allulose, Sorbitol, Pectin Excipient, Luo Han Guo Excipient, Xanthan Gum, ARABINOSE, Calcium Lactate, Xylitol Excipient, Tapioca, Tagatose Excipient, Sodium Saccharin Excipient, Isomaltitol Excipient, D Xylose Excipient, Maltitol Excipient

EXCIPIENTS BY APPLICATIONS

Taste Masking, Fillers, Diluents & Binders, Thickeners and Stabilizers, API Stability Enhancers, Chewable & Orodispersible Aids, Coating Systems & Additives, Disintegrants & Superdisintegrants, Emulsifying Agents

excipientsByApplications
Taste Masking
Fillers, Diluents & Binders
Thickeners and Stabilizers
API Stability Enhancers
Chewable & Orodispersible Aids
Coating Systems & Additives
Disintegrants & Superdisintegrants
Emulsifying Agents

INSPECTIONS & REGISTRATIONS

2 FDA

inspections
2 FDA

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

About

Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.

CPhI South East AsiaCPhI South East Asia

Industry Trade Show

Not Confirmed

16-18 July, 2025

MITEC, Kuala Lumpur, Malaysia
CPhI WW FrankfurtCPhI WW Frankfurt

Industry Trade Show

Booth #12.0F117

28-30 October, 2025

Frankfurt
PharmexPharmex

Industry Trade Show

Not Confirmed

04-07 July, 2025

Tehran, Iran

CONTACT DETAILS

Click the arrow to open the dropdown

Country

U.S.A

Address

45 Rasons Ct., Hauppauge, NY 11788

Telephone

+1 6317381188

sales@rochemintl.com

Website

https://rochemintl.com/

https://www.linkedin.com/company/rochem-interntational-inc./

YouTube

https://www.youtube.com/channel/UC1jKsBYO79Ff1yWAHZLsF9w

Digital content

Explore the latest content creation from this company

INTERVIEW #SpeakPharma

“We’re striving to support a competitive and globally diverse supply chain for our customers”

This week, SpeakPharma interviews Matt Thiel, President of Rochem International, a company that acts as a strong bridge between the East and the West by taking high quality ingredients manufactured mainly in China to manufacturers of food, nutritionals and pharmaceuticals in the regulated markets of the West. Today, Rochem not only supplies ingredients, but also provides customers with regulatory compliance and documentation. The company has been diversifying to other countries for sourcing raw materials and ingredients. This way, it seeks to support a competitive and ever-evolving supply chain for its customers, informs Thiel.Rochem has a unique business model. When was the business idea conceived?Rochem’s journey is closely linked to the story of our founder, Robyn Frisch, born and educated in China, who began her career in the chemical and pharmaceutical industry. In the 1980s, she joined one of the largest trading companies in China that specialized in chemicals and pharmaceutical raw materials. Robyn travelled throughout China and visited many different chemical and drug manufacturers, which allowed her to develop a broad understanding of the sourcing, manufacturing, and supply process.After relocating to the United States in 1990, Robyn continued to work in the industry, but felt the need for a highly trusted intermediary between leading ingredient manufacturers in China and manufacturers in the highly regulated, developed markets of the West. In 1994, she took the entrepreneurial leap and founded Rochem International Inc., which was first run out of her home office in Queens, New York.Rochem has been growing rapidly ever since and now operates 16 offices throughout North America and Europe, including an office in China for sourcing, auditing, and logistics. Today, we are a global leader in developing, sourcing, and distributing predominantly Chinese-origin products to the world’s largest companies in the regulated markets of Human and Animal Health, Nutritional, Dietary Supplement, Food, Beverage, and Confectionery arenas.How difficult was it to win the trust of manufacturers in the developed markets?Since the beginning, we have focused on high-quality products, professionalism, and transparency, which helps us win the trust of our partners.We deliver the highest quality ingredients for both over-the-counter (OTC) and prescription (Rx) medications for both human and animal applications, and also excel in peptides. Our customers trust us for FDA-compliant sweeteners, vitamins, nutraceuticals, and food additives. The largest food and beverage companies in the world rely on us for a wide variety of ingredients that meet or exceed strict quality criteria.With so much talk of regulatory violations, contamination and sub-standard quality APIs coming out of China and India, has retaining customers in the developed world been a challenge?We maintain a stringent and verifiable auditing program which ensures that our valued partners are FDA-compliant and are using current Good Manufacturing Practices (cGMPs) in all their operations and systems.Our team dedicates a great deal of time identifying and recruiting quality suppliers with verified credentials that supply top-grade ingredients. Our sourcing headquarters in Qingdao, China, is equipped to exceed our customers’ requirements for quality and diversity. We manage the entire supply chain from sourcing to delivering ingredients with the sole purpose of maximizing our customers’ competitive advantage. This has made it possible for us to grow exponentially over the years.What kind of regulatory services does Rochem offer?We have 14 regulatory staff members who assist our customers with numerous types of cGMP documentation and technical support. We train and audit our partners to ensure FDA-compliant cGMPs are in their operations and systems. Our audits are extremely thorough and include an agenda, summary report, and a corrective action report, when applicable.We are proud to say our regulatory team is well versed in ICH Q7A and CFR law and ensures that all required Rochem-represented API suppliers have self-identified with the FDA. We audit our manufacturers on a strict routine basis based on the USFDA’s six system quality inspection approach.Our facilities have been inspected by the USFDA and audited by several multinational organizations for cGMP compliance. Our internal global operations are fully cGMP compliant as per the requirements in ICH Q7 ‘GMP Guide for Active Pharmaceutical Ingredients’ as well as in IPEC and USP’s ‘Good Distribution Practices’. We have made a name for ourselves in the European and US markets.Has Rochem embarked on any diversification programs?We plan to constantly evolve and expand our supply chain. Currently, we are focusing on diversifying to multiple countries (of origin of raw materials/ingredients) to support a globally diverse supply chain for our customers. We will continue to focus on supplying ingredients to regulated markets from sources in Asia and other cost competitive parts of the world for all our product lines.Our goal is to focus on staying at the forefront of regulation and compliance issues and continue developing long-term, strategic partnerships with our customers and suppliers.Where do you want to see Rochem in the near future?From a small, one-room office in Robyn’s home, to a global importer of the highest quality ingredients with 16 offices worldwide, we wish to continue this momentum by entering new markets and products with our strong, diverse, and ever-expanding supply chain relationships. While we have a strong core product line that is the foundation of our company, we also strive to become the product trend experts in our field and demonstrate the ability to grow with the market. We value innovation and having the resources to offer new and exciting ingredients to our customers that will positively impact their businesses.

Impressions: 1925

CORPORATE CONTENT #SupplierSpotlight

Product List 2024

Open PDF

Upload

Corporate Presentation

Open PDF

Upload

Animal Health APIs 2024

Open PDF

Upload

Food & Beverage Ingredients Brochure 2024

Open PDF

Upload

Nutritional Product Brochure 2024

Open PDF

Upload

CEO Interview

Futaste Documentary

DATA COMPILATION #PharmaFlow

Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.